Evidence map›Paper›PMID 35005254›Full record

ReviewJournal of clinical tuberculosis and other mycobacterial diseases2022

Anti-tuberculosis drug resistance in Slovakia, 2018-2019: The first whole-genome epidemiological study.

Matúš Dohál, Věra Dvořáková, Miluše Šperková, Igor Porvazník, Andrea Maurizio Cabibbe, Alberto Trovato, Andrea Spitaleri, Erik Michael Rasmussen, Kristián Pršo, Mária Škereňová and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical tuberculosis and other mycobacterial diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Matúš DohálDepartment of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University, Slovakia.
Věra DvořákováNational Reference Laboratory for Mycobacteria, National Institute of Public Health, Praha, Czech Republic.
Miluše ŠperkováNational Reference Laboratory for Mycobacteria, National Institute of Public Health, Praha, Czech Republic.
Igor PorvazníkNational Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovakia, Faculty of Health, Catholic University, Ružomberok, Slovakia.
Andrea Maurizio CabibbeEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Alberto TrovatoEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Andrea SpitaleriEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Erik Michael RasmussenInternational Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark.
Kristián PršoDepartment of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University, Slovakia.
Mária ŠkereňováBiomedical Center Martin, Department of Molecular Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia, Department of Clinical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia.
Daniela Maria CirilloEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Ivan SolovičNational Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovakia, Faculty of Health, Catholic University, Ružomberok, Slovakia.
Juraj MokrýDepartment of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University, Slovakia.
Comenius University Bratislava · SKCatholic University in Ruzomberok · SKIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleNational Institute of Public Health · CZStatens Serum Institut · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe resistance of

designA total of 495 patients with pulmonary TB, who were referred to National Reference Laboratory for Mycobacteriology (Vyšné Hágy, Slovakia) in the years 2018-2019, were studied. Out of the total of 495 patients, 4 XDR-TB (0.8%) and 8 (1.6%) MDR-TB isolates were identified by conventional drug susceptibility testing on Löwenstein-Jensen solid medium and subjected to whole genome sequencing. Sequencing data were evaluated for molecular-epidemiological analysis and identification of resistance patterns.

resultsPhylogenetic and cluster analysis showed extensive recent transmission events and the predominance of Euro-American lineage 4.7 in Slovakia. However, phylogenetic analysis revealed the circulation of several lineages that originally occurred in Eastern European countries. Resistance patterns for first- and second-line antituberculosis drugs characterized by whole genome sequencing were in high concordance with the results of phenotypic drug susceptibility testing.

conclusionForty percent of at least MDR-TB isolates were not genetically linked, indicating that appropriate measures should be taken to monitor and prevent the spread of drug-resistant tuberculosis within the country as well as in other regions.

Indexed as

Extensively drug resistantMulti drug resistantSlovakiaTuberculosisWhole genome sequencing

Identifiers

PMID35005254
PMCPMC8717600
OpenAlexW4200569837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.